Posts

Posted on

IIROC Trading Halt – SZLS.WS

Canada NewsWire

TORONTO, Dec. 4, 2020 /CNW/ – The following issues have been halted by IIROC:

Company: StageZero Life Sciences Ltd.

TSX Symbol: SZLS.WS

Reason: Pending Closing

Halt Time (ET): 8:00 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Posted on

Joe Rogan Teams Up with Kill Cliff to Create the Flaming Joe

Flaming Joe, a CBD Infused Beverage by Kill Cliff, is Totally Lit

ATLANTA, Dec. 04, 2020 (GLOBE NEWSWIRE) — Kill Cliff, America’s undisputed clean energy drink champion, is proud to announce a collaboration with Joe Rogan to create the Flaming Joe. Straight from the mind of Rogan, this incredibly unique, spicy pineapple fusion is the latest edition to the country’s best-selling line of CBD beverages.

The Flaming Joe contains 25mg of CBD, derived from 125mg of broad-spectrum hemp, B-vitamins, electrolytes, and plant extracts.  As with all Kill Cliff drinks, there is no sugar or artificial ingredients. The flavor is bold and spicy.  

Rogan, the world’s top podcaster, is a longtime advocate of CBD for mental and physical well-being.  It is a regular topic and shared interest with a multitude of celebrity guests, ranging from Mike Tyson and Miley Cyrus to military veterans like Andy Stumpf. 

As a Kill Cliff partner and power user, it only made sense to work together to create twelve ounces of liquid magic. As Rogan says, “It’s amazing how much good you can get out of a 24-kilogram kettlebell and a can of Kill Cliff CBD.”  

“Working with Rogan on this drink was a really cool experience for the entire Kill Cliff team,” says John Timar, president of Kill Cliff. “Our guys, Jerry Barker and Mitch Brown, did a remarkable job nailing the flavor concept and creating an awesome can design worthy of this product.”

Since entering the CBD market last year, Kill Cliff has pioneered the industry, gaining massive distribution, accelerating brand engagement and attracting top athletes and high-profile celebrities. In fact, earlier this year, John Brenkus, the six-time Emmy-Award winning creator, host and producer of ESPN Sport Science, joined Kill Cliff as Chief Marketing Officer.  

“Today’s consumer is rightfully more aware than ever of what they put in their bodies. Kill Cliff is by far the best tasting and healthiest energy drink available,” Brenkus concluded. “I’m honored to be part of the clean energy drink company that is literally disrupting the industry.”

The new Flaming Joe is available to order now at killcliffcbd.com. Crush your cravings with all the Kill Cliff CBD flavors including Flaming Joe, Strawberry Daze, Mango Tango, The G.O.A.T and Orange Kush. Check out Kill Cliff’s clean energy drinks at killcliff.com.

About KILL CLIFF 

Founded and created by a Navy SEAL with the spirit of giving back to the community, KILL CLIFF® makes clean and delicious energy drinks. KILL CLIFF products deliver clean fuel for the active lifestyle, providing energy, hydration and nutrients without all the junk so many beverages have today. Kill Cliff was just voted one of the 250 most disruptive brands by IAB and is poised to make significant gains in the multi-billion dollar beverage market. Headquartered in Atlanta, the KILL CLIFF team includes civilians and accomplished military veterans and is absolutely committed to serving and supporting the Navy SEAL community. KILL CLIFF honors the dedication and sacrifice made by these warriors and their families by donating a portion of the proceeds through their Official Partnership with the Navy SEAL Foundation. Visit KillCliff.com and follow KILL CLIFF on Facebook, Twitter, YouTube, and Instagram @killcliff.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/94b12ae5-0add-4b6d-833c-7e059b8f36bf



Media Inquiries
Jenn McFerron Sloan
[email protected]

Posted on

Hiring Decreases in November as Uncertainty Catches Up to Small Business Sector

Hiring Decreases in November as Uncertainty Catches Up to Small Business Sector

With the holiday shopping season underway, the CBIZ Small Business Employment Index reverses after two months of gains

CLEVELAND–(BUSINESS WIRE)–
The CBIZ Small Business Employment Index (“SBEI”) reported a 1.06% seasonally adjusted decrease for November, veering from historical year-end data that is largely supported by the holiday shopping season. Waning consumer confidence, increasing COVID-19 cases, travel restrictions and political rhetoric have weighed on small businesses and been reflected in their hiring practices. The CBIZ SBEI tracks payroll and hiring trends for over 3,500 companies that have 300 or fewer employees, providing broad insight into small business trends.

“The CBIZ SBEI reveals a startling decline in November, further illuminating the unique headwinds the small business landscape has faced this year,” said Philip Noftsinger, Executive Vice President, CBIZ, Inc. “While small business hiring increased in September and October, the tables turned in November with escalating uncertainty.”

The sentiment from the ADP and Moody’s employment report was more upbeat, with private-sector jobs climbing by 307,000 on a month-over-month, seasonally adjusted basis, and small businesses reporting 110,000 new jobs. The ADP and Moody’s report counts small businesses as companies with 49 or fewer employees, while the CBIZ SBEI uses data from companies with 300 employees or fewer.

From a geographic standpoint, the West (1.36%) was the only U.S. region to see hiring increase, as the Northeast (-1.79%), Central (-1.43%) and Southeast (-0.67%) scaled back hiring. Hiring also decreased for states that opened on or before May 15 (-1.73%) and states that opened afterward (-0.97%).

A number of industries saw hiring decline, notably Technology and Life Sciences, Construction, Accommodation and Food Services, and Real Estate. On a more positive note, hiring increased in Arts and Entertainment, which had experienced depressed trends since the spring. Hiring grew among Non-Profits as well.

“We’re hopeful that consumer activity throughout the holiday shopping season will move the needle for small business hiring in December,” Noftsinger added. “Early returns on the season indicate favorable trends, but threats from COVID-19 and potential economic shutdowns remain in play.”

To view an infographic with data from the employment index, visit the CBIZ website.

Additional takeaways from the November SBEI include:

November’s snapshot: 19% of companies in the index increased staffing, 55% reported consistent employment levels and 26% decreased staffing.

Industries at a glance: Technology and Life Sciences, Construction, Accommodation and Food Services, and Real Estate saw hiring decline. Meanwhile, hiring improved for Arts and Entertainment in addition to Non-Profits.

Geographical hiring: Hiring decreased in three of the four major regions, including the Northeast, Central and Southeast. The West, on the other hand, expanded hiring.

What’s next? With the holiday shopping season afoot, consumer activity will likely play a deciding role in small business hiring in December, coupled with effects from the COVID-19 pandemic.

Editor’s note:

(1) The SBEI illustration is licensed under a Creative Commons Attribution-NoDerivs 3.0 Unported License. Based on our work at https://www.cbiz.com.

Follow CBIZ on Twitter at @CBZ or on Facebook.

About CBIZ, Inc.

CBIZ, Inc. provides professional business services that help clients better manage their finances and employees. CBIZ provides its clients with financial services including accounting, tax, financial advisory, government health care consulting, risk advisory, real estate consulting and valuation services. Employee services include employee benefits consulting, property and casualty insurance, retirement plan consulting, payroll, life insurance, HR consulting and executive recruitment. As one of the largest accounting, insurance brokerage and valuation companies in the United States, the company’s services are provided through more than 100 company offices in 33 states. CBIZ Employee Services Organization is a division of CBIZ Benefits & Insurance Services, Inc.

Sandy McKenzie

Gregory FCA for CBIZ

[email protected]

610-228-2147

KEYWORDS: Ohio United States North America

INDUSTRY KEYWORDS: Professional Services Technology Other Technology Insurance Human Resources Finance

MEDIA:

Logo
Logo
Posted on

Cellular Biomedicine Group Announces Data to be Presented at 2020 ASH Annual Meeting

– C-CAR088 Anti-BCMA CAR-T Cell Therapy for Multiple Myeloma (MM)

– C-CAR039 Novel Anti-CD19/CD20 Bi-Specific CAR-T Cell Therapy for Relapsed/Refractory (r/r) B-Cell NHL

– C-CAR066 CAR-T Cell Therapy for B-Cell NHL Patients Who Are Relapsed/Resistant Following CD19 CAR-T Therapy

PR Newswire

GAITHERSBURG, Md. and SHANGHAI, Dec. 4, 2020 /PRNewswire/ — Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today that three abstracts relating to its immuno-oncology drug development have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held as a virtual event on December 5-8, 2020.

 

Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

C-CAR088
Abstract Title: An Anti-BCMA CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma
Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Novel Therapies Targeting B Cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma
Date: Saturday, December 5, 2020
Time: 1:15pm PST
Abstract Online: https://ash.confex.com/ash/2020/webprogram/Paper138734.html
A copy of the presentation materials will be made available on the Investor Relations section of the Company website following the presentation.

C-CAR039
Abstract Title: Developing a Novel Anti-CD19/CD20 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Relapsed/Refractory (r/r) B-Cell NHL
Online only: https://ashpublications.org/blood/article/136/Supplement%201/8/473629/Developing-a-Novel-Anti-CD19-CD20-Bi-Specific 

C-CAR066
Abstract Title: Early Clinical Results of a Novel Anti-CD20 Chimeric Antigen Receptor (CAR)-T Cell Therapy for B-Cell NHL Patients Who Are Relapsed/Resistant Following CD19 CAR-T Therapy
Online only: https://ashpublications.org/blood/article/136/Supplement%201/8/473636/Early-Clinical-Results-of-a-Novel-Anti-CD20 

About Cellular Biomedicine Group, Inc.

Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. The company conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory. The Company’s GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. Its Shanghai facility includes a “Joint Laboratory of Cell Therapy” with GE Healthcare and a “Joint Cell Therapy Technology Innovation and Application Center” with Thermo Fisher Scientific. These partnerships focus on improving manufacturing processes for cell therapies. CBMG currently has ongoing CAR-T Phase I clinical trials in China. The China NMPA (formerly CFDA) approved the Company’s IND application for a Phase II trial for AlloJoin®, CBMG’s “Off-the-Shelf” allogenic haMPC therapy for the treatment of Knee Osteoarthritis (KOA), and has accepted the Company’s IND application for a Phase II trial for ReJoin® autologous haMPC therapy for the treatment of KOA. The NMPA has also accepted CBMG’s dossier for an IND application for clinical trials of anti-BCMA CAR-T. CBMG is included in the broad-market Russell 3000® Index the small-cap Russell 2000® Index and the Loncar China BioPharma index. To learn more about CBMG, please visit www.cellbiomedgroup.com.

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities, investments, and other statements that are not descriptions of historical facts, including our expectations regarding our immuno-oncology and regenerative medicine clinical trials, including trials of our CAR-T Cell therapies, may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including risks regarding our ability to execute on proposed new products, services or development thereof, the results of our clinical research and development, particularly as they relate to CAR-T Cell therapies, regulatory infrastructure governing cell therapy and cellular biopharmaceuticals, our ability to enter into agreements with any necessary manufacturing, marketing and/or distribution partners for purposes of commercialization, our ability to seek intellectual property rights for our product candidates, uncertainty regarding competition in the industry in which we operate, overall market conditions, and the impact of the COVID-19 pandemic on our operations, including risks associated with the evolving COVID-19 pandemic and actions taken in response to it. Generally, forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” “promising,” or “continue” or similar terms or the negative of these terms. These statements reflect CBMG’s current views with respect to future events or to its future activities and involve known and unknown risks, uncertainties and other factors which may cause CBMG’s actual activities, actions or achievements to be materially different from any future activities, actions or achievements expressed or implied by the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Company/Investor Contact:
Sarah Kelly
Director of Corporate Communications, CBMG
Phone: (301) 825-5320
Email: [email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cellular-biomedicine-group-announces-data-to-be-presented-at-2020-ash-annual-meeting-301186475.html

SOURCE Cellular Biomedicine Group

Posted on

Global Internet of People Inc. Launches NASDAQ IPO Roadshows and Aims to Raise $28 Million to Develop the Knowledge Sharing Ecosystem

Beijing, China, Dec. 04, 2020 (GLOBE NEWSWIRE) — Global Internet of People, Inc. (the Company or “SDH”), a company operates a knowledge sharing and enterprise services platform both online and offline, today announced that following the warm-up of roadshows in Chengdu and Zibo, it is going to conduct Nasdaq IPO roadshows in multiple cities in China such as Hangzhou, Shanghai, Shenzhen and Beijing through December 8 to13, 2020, Beijing Time, aiming to raise $28 million (approximately RMB185 million) from this initial public offering.

According to the Prospectus filed with U.S. Securities and Exchange Commission, SDH provided online and offline membership services and enterprise services to 1,467 members and 5.49 million users by the end of September 2020 through its 51 local centers in 35 cities in China. The online knowledge sharing and consulting platform brings together 1,548 prestige mentors and experts to provide high-quality services for enterprise and individual users. SDH focus on knowledge sharing and enterprise cooperation services via mobile applications and local centers, and the number of users has increased from 0.8 million in May 2017 to 5.49 million in September 2020. By revenue segmentation, SDH’s major businesses falls into enterprise comprehensive tailored services, member services, sponsorship advertising services, enterprise consulting services, online services and sale of merchandises services. During the first six months of 2020, revenue increased 12.2% to $6.51 million year-on-year. Net income increased 2% year-on-year to $2.29 million. For the full year of 2019, revenue increased by 32.4% year-on-year to $17.9 million, while net income increased by 30.4% year-on-year to $9.75 million. During the first six months of 2020 and 2019, operating margins were 36% and 42%, respectively. The proceed raised from IPO will be used to 1) content providing (both in-house and third-party providers) 30%, 2) software and hardware upgrade 20%, 3) marketing, branding and sales 20%, 4) acquisition of knowledge sharing providers and consulting companies 25%, and 5) personnel training and recruitment 5%. SDH has received an approval letter from NASDAQ on November 11, 2020 to list on The Nasdaq Capital Market with symbol ticker “SDH”.

Mr. Hu Haiping, Chairman of SDH, said, “Developing an ecosystem of knowledge sharing and an ecosystem of enterprise growth services are still important growth point for the Company in the future. Listing in the NASDAQ is very important to the long-term strategic layout of SDH in terms of our brand upgrade and obtaining capital support from the market.”

In the new economic era of accelerated innovation, transformation and upgrading of China’s economy, the promotion of entrepreneurs’ business wisdom, the establishment of digital enterprise economic cooperation system and the establishment of enterprise growth service ecosystem are required to catch up with the times and the new momentum of economy. In the face of the needs of tens of millions of enterprises moving towards high-quality development, SDH was incepted in 2016, and take “knowledge sharing and enterprises collaboration” as the concept to spread business wisdom, integrate industrial resources, help enterprises upgrade and innovation, and develop rapidly. The Company has won the support and affirmation of many users. Intelligent economy is a higher form of digital economy, and SDH’s smart connected network is a typical form of intelligent economy. Over the past four years, the Company has continued to develop, stands out with excellent performance, and position itself to be a “dark horse” in the internet of intelligence field.

About Global Internet of People Inc.

Headquartered in Beijing and Shanghai, Global Internet of People Inc. operates an online knowledge sharing and enterprise service platform, both online, via our mobile application “Shidonghui App” (the “APP”), and offline, through local offices directly operated by us in Beijing, Shanghai and Hangzhou, as well as 51 local centers in 35 cities throughout the PRC. The main services we offer to Users on our APP are (1) Questions and Answers (Q &A) Sessions and (2) streaming of audio and video courses and programs. The offline services we offer to our Members are study tours and forums. For more information about the Company, please visit: www.sdh365.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements.  Specifically, the Company’s statements regarding trading on the NASDAQ Capital Market and closing the IPO are forward-looking statements.  Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following:  the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission.  For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward‐looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

At the Company:

Hongfei Zhao
Email: [email protected]
Phone: +86 18001021718

Investor Relations:

Janice Wang     
EverGreen Consulting Inc.
Email: [email protected]
Phone: +86 13811768559 / +1-908-510-2351



Posted on

Marizyme, Inc. Expands Executive Team, Board of Directors

Steven Brooks, M.D., MBA, FACC – Appointed EVP of Medical and Regulatory Affairs, Chief Medical Officer

Donald Very, Ph.D. – Appointed EVP, Research & Development

William Hearl, Ph.D. – Named Independent Member of Board of Directors

PR Newswire

JUPITER, Fla., Dec. 4, 2020 /PRNewswire/ — Marizyme, Inc. (OTCQB: MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has expanded the company’s executive team and board of directors with three new appointments.

Steven Brooks, M.D., MBA, FACC, has been named EVP of Medical and Regulatory Affairs, Chief Medical Officer for Marizyme.  Dr. Brooks brings more than 20 years of experience supporting the commercialization of medical innovation, including medical devices, mHealth, drugs, biologics and combination products, to this role.

Donald Very, Ph.D., has also joined the executive management team as  EVP, Research & Development.  Dr. Very has more than 30 years of experience in all phases of pharmaceutical and diagnostic assay research and device development, including performance validation, clinical trial design and implementation, and regulatory approvals.

William Hearl, Ph.D., an experienced and successful life science entrepreneur who is adept at brokering mutually beneficial partnerships and identifying non-traditional collaborations and investment opportunities, has been named an Independent Member of Marizyme’s Board of Directors.

“Drs. Brooks and Very will provide Marizyme with a wealth of scientific, regulatory and capital markets expertise, all of which is critical as the company seeks to grow its life science assets and elevate its financial position,” said Dr. Neil J. Campbell, Marizyme’s CEO and President and a Member of its Board of Directors. “Dr. Brooks and Dr. Very will provide experience and leadership in building Marizyme’s pipeline of therapies that address urgent needs related to higher mortality and costs in the acute care space.”

Mr. James Sapirstein, Marizyme’s Executive Chairman, said,  “Dr. Hearl’s track record of brokering mutually beneficial partnerships and identifying non-traditional collaborations and investment opportunities will be invaluable in bolstering Marizyme’s shareholder value.”

Dr. Hearl, Independent Member of Marizyme’s Board of Directors, commented, “I am excited to join Marizyme’s board and work to support the company as it builds the promising suite of acute care therapies.”


Executive Appointments


Steven Brooks, M.D., MBA, FACC – EVP of Medical and Regulatory Affairs, Chief Medical Officer

Steven Brooks, M.D., MBA, FACC, has more than 20 years of experience supporting the commercialization of medical innovation, including medical devices, mHealth, drugs, biologics and combination products. He was the Principle of Brooks Medtech, LLC, a medical technology consulting firm. Dr. Brooks’ interests include evidence development, clinical trial design and execution, regulatory and reimbursement strategy and healthcare market strategy.

Dr. Brooks was previously an interventional cardiologist at University of Maryland Medical Center and private practice. He also served as a medical officer within FDA’s CDRH in the Division of Cardiovascular Devices.

Dr. Brooks has held positions with the life science consulting firms NDA Partners, Popper & Company, and Sage Growth Partners. He is CMO for Global Interconnect and previously held the positions of CMO for Cardiocube, LLC and VP of Regulatory Affairs and Health Economics for Ablative Solutions.

Dr. Brooks earned his M.D. at the University of Pittsburgh School of Medicine, and his Residency in Cardiology and Interventional Cardiology Fellowships at University of Pittsburgh Medical Center. He received his MBA from the Johns Hopkins Carey School of Business in the Business of Medicine Program, and his B.A. at Duke University.

Donald Very, Ph.D.  – EVP, Research & Development

Donald Very, Ph.D., has more than 30 years of device, diagnostic and, pharmaceutical compound/assay development and performance qualification experience in such diverse clinical areas as oncology, infectious disease, cardiovascular and, metabolic disease. Dr. Very has extensive experience in all phases of pharmaceutical and diagnostic assay research and device development, performance validation, clinical trial design and implementation, and regulatory approval.

Dr. Very previously served as Senior Vice President of Mosaigen, a global science & technology development corporation; and President, CEO, and Founder of Naviter Bioanalytics, LLC, a private consulting firm specializing in technological due diligence, bioanalytical method development, performance qualification, and regulatory approval.

Dr. Very also previously served in senior executive and scientific positions at Helomics Corporation, Ancera, Inc., the Institute for Bioanalytics, LLC (IBA), and the Bayer Corporation. Dr. Very began his career as a researcher and supervisor of laboratories affiliated with the U.S. Army Medical Research Unit in the Republic of Korea. 

Dr. Very is a frequently invited speaker at national and international scientific symposia. He received his B.S. degree in Biology from the University of Notre Dame, his M.S. degree in Biology from the University of Texas at San Antonio, and his Ph.D. in Microbiology/Immunology from Boston University.


Board of Directors Appointment


William Hearl, Ph.D.  – Independent Member of Board of Directors

William Hearl, Ph.D., the founder of Immunomic Therapeutics, Inc. (ITI), is an experienced and successful life science entrepreneur who is adept at brokering mutually beneficial partnerships and identifying non-traditional collaborations and investment opportunities.

Dr. Hearl founded ITI in 2006 to commercially develop LAMP technology, which was sub-licensed to Geron Corporation and later led to license agreements valued at  $300+ million with Japan-based Astellas for next generation allergy vaccines based on the LAMP platform.

Dr. Hearl is also a founder of Capital Genomix, Inc., a Maryland-based biomarker and drug discovery company, and served as its CEO and Chief Scientific Officer. He was instrumental in CGI’s acquisition of the Dynex Technologies division of Thermo Scientific, which was subsequently divested and yielded a remarkable tenfold return to the company.

Dr. Hearl is also responsible for the acquisition and development of the core technologies of Capital Genomix, the GeneSystem320™ and the ImmunoMouse™.

Dr. Hearl began his career as a bench scientist at Electro-Nucleonics, Inc., where he developed blood-based diagnostics for HIV, HTLV-I and Hepatitis C. He later directed the immunodetection group at Life Technologies and became the director of research and development at Kirkegaard & Perry Laboratories, Inc.

Dr. Hearl earned his Ph.D. in biochemistry from the University of Tennessee and B.S. from East Tennessee State University.

About Marizyme, Inc.

Marizyme is an integrated life sciences company dedicated to the acquisition, development and commercialization of therapies that minimize mortality and costs in the acute care space. The Company’s flagship product, DuraGraft®, is an intra-operative vascular graft storage solution that inhibits endothelial damage, leading to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft enhances coronary artery bypass grafting (CABG) surgical outcomes by significantly reducing major adverse cardiac events such as repeat revascularization and myocardial infarction. DuraGraft is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease-based therapeutic Krillase® platform. Krillase is not approved for use in the U.S. For more information about Marizyme, visit www.marizyme.com.

Forward-Looking Statements

This press release may contain certain forward-looking statements, including those relating to the Marizyme’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable, and complete. However, a variety of factors, many of which are beyond the Company’s control, affect the Company’s operations, performance, business strategy and results and there can be no assurances that the Company’s actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. Forward-looking statements may be identified using forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, including those risks set forth in the Company’s risk factor disclosure in the reports that Marizyme files with the Securities and Exchange Commission (SEC File No. 000-53223), uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT

Tiberend Strategic Advisors, Inc.

Investors
Maureen McEnroe, CFA/Miriam Miller
212-375-2664 / 212-375-2694
[email protected]
[email protected]

Media
Ingrid Mezo
646-604-5150
[email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/marizyme-inc-expands-executive-team-board-of-directors-301186309.html

SOURCE Marizyme, Inc.

Posted on

Sea Selected for the Award of Digital Full Bank License in Singapore

Sea Selected for the Award of Digital Full Bank License in Singapore

  • Digital bank initiative will build on Sea’s long-standing commitment to supporting the development of the digital economy in its home market, as well as Singapore’s role as a global hub for technology and financial services.
  • Emphasis on addressing the unmet financial services needs of young consumers and SMEs will empower more Singaporeans to thrive in the digital economy.

SINGAPORE–(BUSINESS WIRE)–
SeaLimited (NYSE: SE) (“Sea” or the “Company”) today announced that it has been selected for the award of a license to operate a digital full bank in Singapore. The Monetary Authority of Singapore announced earlier today that Sea has been selected for the award of a digital full bank license, the first time such a license is being awarded in Singapore.

“Sea’s mission is to better the lives of consumers and small businesses through technology, and we are honoured to be selected by the Monetary Authority of Singapore for the award of a digital full bank license and to have the opportunity to offer digital banking services addressing the underserved financial needs of young consumers and SMEs in Singapore,” said Forrest Li, Chairman and Group Chief Executive Officer of Sea. “We are thankful to the Monetary Authority of Singapore for entrusting Sea with this important responsibility of broadening access to the opportunities of digitalisation. As a proudly homegrown company, we look forward to further contributing to the long-term development of our nation’s digital economy, creating more employment opportunities in Singapore, and empowering our whole community to thrive in the digital era.”

Through its three platforms – Shopee, Garena, and SeaMoney – Sea is already deeply integrated into Singapore’s digital economy with young consumers and SMEs. Its digital bank will draw on insights about the needs of these users from across Sea’s digital ecosystem to innovate processes, products, and services that will improve the lives of young consumers and SMEs in Singapore and support the growth of the country’s digital economy by reducing the barriers to accessing financial services through technology.

About Sea Limited

Sea Limited (NYSE: SE) is a leading global consumer internet company founded in Singapore in 2009. Our mission is to better the lives of consumers and small businesses with technology. We operate three core businesses across digital entertainment, e-commerce, as well as digital payments and financial services, known as Garena, Shopee, and SeaMoney, respectively. Garena is a leading global online games developer and publisher. Shopee is the largest pan-regional e-commerce platform in Southeast Asia and Taiwan. SeaMoney is a leading digital payments and financial services provider in Southeast Asia.

Investors / analysts: [email protected]

Media: Martin Reidy, [email protected]

KEYWORDS: Asia Pacific Singapore

INDUSTRY KEYWORDS: Technology Finance Banking Professional Services Small Business Software Internet Retail Online Retail

MEDIA:

Posted on

Laurentian Bank Financial Group declares dividends on its common shares

MONTREAL, Dec. 04, 2020 (GLOBE NEWSWIRE) — At its meeting held on December 3, 2020, the Board of Directors of the Laurentian Bank of Canada (TSX: LB) (the “Bank”) declared a regular quarterly dividend of 40 cents per share on the common shares payable on February 1, 2021 to the holders of record at the close of business on January 4, 2021.

The above-mentioned dividends are designated as eligible dividends for the purposes of the Income Tax Act (Canada) and any similar provincial and territorial legislation.

The above-mentioned shares are eligible shares under the Bank’s Shareholder Dividend Reinvestment and Share Purchase Plan (the “Plan”). Consequently, the holders of such shares may elect to reinvest their dividends in newly issued common shares of the Bank. Such purchases will be made at the applicable investment price as defined in the Plan, less a discount of 2%, and no brokerage commissions or service charges of any kind will apply.

In addition, holders of such shares are entitled to make monthly optional cash payments to purchase additional common shares in accordance with the terms of the Plan.

For more information, please contact Computershare Trust Company of Canada at 1-800-564-6253. Beneficial or non-registered owners of common and preferred shares must contact their financial institution or broker for instructions on how to participate in the Plan.

About Laurentian Bank Financial Group

Founded in 1846, Laurentian Bank Financial Group is a diversified financial services provider whose mission is to help its customers improve their financial health. The Laurentian Bank of Canada and its entities are collectively referred to as Laurentian Bank Financial Group (the “Group” or the “Bank”).

With more than 2,900 employees guided by the values of proximity, simplicity and honesty, the Group provides a broad range of advice-based solutions and services to its personal, business and institutional customers. With pan-Canadian activities and a presence in the U.S., the Group is an important player in numerous market segments.

The Group has $44.2 billion in balance sheet assets and $27.8 billion in assets under administration.

Information :

Fabrice Tremblay
Advisor, Communications
Office: 514 284-4500, extension 40020
Mobile: 438 989-6070
[email protected]



Posted on

Pressure BioSciences Proposed Acquisition Partner Cannaworx, Inc. Announces December 2020 Launch Date for FDA Registered Immune Booster

– Designed to Help the Immune System Provide Important Protection Against Invading Pathogens

– ImmunaZin is Unique as a Hemp Seed Oil-Enhanced, FDA Registered Immune Booster with Prebiotic

PR Newswire

SOUTH EASTON, Mass., Dec. 4, 2020 /PRNewswire/ — Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that its proposed acquisition partner Cannaworx, Inc. has set December 2020 as the commercial launch date for its patented immune booster supplement: ImmunaZin™.  Cannaworx believes that post-launch, this product will be one of very few OTC (over the counter), FDA registered, hemp seed oil-enhanced supplements with an immune booster claim. 

The immune system’s role is to keep us healthy by defending against invaders (e.g., bacteria and viruses). It is therefore important to keep our immune systems as strong and effective as possible. Healthy living is the main strategy recommended  to achieve this goal. Another strategy is to augment healthy living with powerful, high quality immune boosters, which have recently become very popular, e.g., the global immune booster market is estimated to exceed $25B by 2025 and the market has been spurred further by the on-going COVID-19 pandemic.

Dr. Bobby Ghalili, co-founder of Cannaworx, said: “The active ingredient in ImmunaZin is a patented, proprietary blend of 44 amino acid fragments derived from the enzyme pepsin. ImmunaZin works by increasing the number of T helper cells in the human body. T helper cells enable cells called macrophages to kill and consume bacteria, viruses, and other invaders. This makes ImmunoZin strikingly different from most other immune boosters on the market today, as it is a novel and potent T cell stimulator, enabling the immune system to aggressively defend against invasions of disease-causing pathogens.”

Dr. Ghalili continued: “To further enhance ImmunaZin’s immune boosting effect, we added hemp seed oil (no THC) to our patented formulation. Hemp seed oil is rich in essential fatty acids (e.g., omega-6 and omega-3) and antioxidants that may help fight inflammation, cancer, diabetes, and heart disease. Omega-3 is also thought to have a positive impact on the bowel microbiome as a prebiotic, providing further support to the immune system. The manufacturing process of the patented 44 amino acid fragment formulation is highly proprietary, protected, and would be nearly impossible to imitate.”

Mr. Jim Morrison, President of Cannaworx, commented: “We have been preparing for the upcoming December 2020 commercial release of ImmunaZin for many months.  We have built an inventory of nearly 20,000 market-ready packages of product and have the materials on hand to prepare and deliver many thousands more. We have developed a strong digital marketing campaign and have readied our internal Five Leaf Labs sales and distribution network (announced on May 19, 2020), We expect to significantly add to our internal capabilities by quickly bringing on one or more “wholesale to retail” and “multi-level-marketing” U.S. and international marketing, sales, and distribution partners. We anticipate that our efforts will result in measurable revenue before the end of 2020, and substantial growth in 2021.”  For additional information on ImmunaZin, please go to www.immunazin.com.

Mr. Richard T. Schumacher, President and CEO of Pressure BioSciences, added: “Our team is excited to be joining a company bringing such an important and valuable product to market, particularly considering its potential role in the fight against the novel coronavirus and other disease-causing pathogens.  We also look forward to bringing our proprietary Ultra-Shear Technology™ (UST™) platform for the processing of high quality nanoemulsions with vanishingly low and controlled droplet sizes, to bear on the emerging compendium of Cannaworx personal care products rolling out in late 2020 and throughout all of 2021.”

The Letter of Intent between Pressure BioSciences, Inc. and Cannaworx, Inc. is subject to certain closing conditions, including completion of all due diligence and acquisition financing.

About Cannaworx, Inc.

Cannaworx, a privately held development-stage company, has developed an extensive portfolio of consumer products, which include FDA-registered, patented/patent-pending diverse product lines. These products capitalize on disruptive delivery systems in the areas of pain relief, pharmaceuticals, skincare, nutraceuticals, and agriculture/veterinary products.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com 

Please visit us on Facebook, LinkedIn, and Twitter.

Press Contacts:

Richard T. Schumacher

President & CEO of PBIO
(508) 230-1828 (T)

Jim Morrison

President of Cannaworx
(508) 230-1829 (F)

 

Cision View original content:http://www.prnewswire.com/news-releases/pressure-biosciences-proposed-acquisition-partner-cannaworx-inc-announces-december-2020-launch-date-for-fda-registered-immune-booster-301186437.html

SOURCE Pressure BioSciences, Inc.

Posted on

Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & Exposition

PR Newswire

SOUTH SAN FRANCISCO, Calif., Dec. 4, 2020 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablets will be presented in two poster presentations at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held virtually December 5-8, 2020. The poster presentations will be made available on the event’s website at https://www.hematology.org/meetings/annual-meeting on Saturday, December 5 at 7:30am PT.

Rigel will present an analysis of long-term safety data on fostamatinib in more than 3,500 patients at various dosing regimens with immune thrombocytopenia (ITP) or rheumatoid arthritis (RA). No new safety signals nor cumulative toxicity were observed with up to 62 months (5.2 years) of continuous treatment in ITP patients and up to 81 months (6.8 years) of continuous treatment in RA patients.

An overview of Rigel’s ongoing Phase 3 clinical trial of fostamatinib in warm autoimmune hemolytic anemia (wAIHA) will also be presented. This is a randomized, double-blind, placebo-controlled study of approximately 90 patients with primary or secondary wAIHA who have failed at least one prior treatment.  This study is based on Rigel’s Phase 2, open-label, multi-center study for the treatment of wAIHA. Results of that study demonstrated that 44% (11/25) of patients had markedly improved hemoglobin (Hgb) levels and adverse events were consistent with those in the fostamatinib safety database.

Additionally, Rigel’s planned Phase 3 clinical trial to evaluate the efficacy and safety of fostamatinib in adult, hospitalized COVID-19 patients was featured in an ASH abstract published in the November 26, 2020, issue of Blood. This is a multi-center, double-blind, placebo-controlled, adaptive design study with a primary endpoint that measures the proportion of subjects who progress to severe/critical disease within 29 days.

Fostamatinib is commercially available in the U.S. under the brand name TAVALISSE® (fostamatinib disodium hexahydrate) tablets, which is the first and only spleen tyrosine kinase (SYK) inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to a previous treatment. The FDA has granted TAVALISSE Orphan Drug designation for the treatment of patients with warm AIHA.


Poster Presentations


Abstract #838

Long-Term Safety Profile of the Oral Spleen Tyrosine Kinase Inhibitor Fostamatinib in Immune Thrombocytopenia (ITP) and Other Diseases

Presenter: Aaron Sheppard, PhD
Session Name: 311. Disorders of Platelet Number or Function: Poster I
Date & Time: Saturday, December 5, 2020: 7:00 AM-3:30 PM PT

Abstract #752

Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study

Presenting Author:
Nichola Cooper, MD
Session Name: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster I
Date & Time: Saturday, December 5, 2020: 7:00 AM-3:30 PM PT


About ITP

In patients with ITP (immune thrombocytopenia), the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP include fatigue, excessive bruising and bleeding. People suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death. In addition to fostamatinib, current therapies for ITP include steroids, blood platelet production boosters (TPO-RAs) and splenectomy. However, not all patients respond to existing therapies. As a result, there remains a significant medical need for additional treatment options for patients with ITP.


About AIHA

Autoimmune hemolytic anemia (AIHA) is a rare, serious blood disorder in which the immune system produces antibodies that result in the destruction of the body’s own red blood cells. AIHA affects approximately 45,000 adult patients in the U.S. and can be a severe, debilitating disease. Warm AIHA (wAIHA), the most common form of AIHA, is characterized by the presence of antibodies that react with the red blood cell surface at body temperature. To date, there are no disease-targeted therapies approved for AIHA, despite the unmet medical need that exists for these patients.


About TAVALISSE


Indication
TAVALISSE® (fostamatinib disodium hexahydrate) tablets is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Important Safety Information

Warnings and Precautions

  • Hypertension can occur with TAVALISSE treatment. Patients with pre-existing hypertension may be more susceptible to the hypertensive effects. Monitor blood pressure every 2 weeks until stable, then monthly, and adjust or initiate antihypertensive therapy for blood pressure control maintenance during therapy. If increased blood pressure persists, TAVALISSE interruption, reduction, or discontinuation may be required.
  • Elevated liver function tests (LFTs), mainly ALT and AST, can occur with TAVALISSE. Monitor LFTs monthly during treatment. If ALT or AST increase to >3 x upper limit of normal, manage hepatotoxicity using TAVALISSE interruption, reduction, or discontinuation.
  • Diarrhea occurred in 31% of patients and severe diarrhea occurred in 1% of patients treated with TAVALISSE. Monitor patients for the development of diarrhea and manage using supportive care measures early after the onset of symptoms. If diarrhea becomes severe (≥Grade 3), interrupt, reduce dose or discontinue TAVALISSE.
  • Neutropenia occurred in 6% of patients treated with TAVALISSE; febrile neutropenia occurred in 1% of patients. Monitor the ANC monthly and for infection during treatment. Manage toxicity with TAVALISSE interruption, reduction, or discontinuation.
  • TAVALISSE can cause fetal harm when administered to pregnant women. Advise pregnant women the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for at least 1 month after the last dose. Verify pregnancy status prior to initiating TAVALISSE. It is unknown if TAVALISSE or its metabolite is present in human milk. Because of the potential for serious adverse reactions in a breastfed child, advise a lactating woman not to breastfeed during TAVALISSE treatment and for at least 1 month after the last dose.

Drug Interactions

  • Concomitant use of TAVALISSE with strong CYP3A4 inhibitors increases exposure to the major active metabolite of TAVALISSE (R406), which may increase the risk of adverse reactions. Monitor for toxicities that may require a reduction in TAVALISSE dose.
  • It is not recommended to use TAVALISSE with strong CYP3A4 inducers, as concomitant use reduces exposure to R406.
  • Concomitant use of TAVALISSE may increase concentrations of some CYP3A4 substrate drugs and may require a dose reduction of the CYP3A4 substrate drug.
  • Concomitant use of TAVALISSE may increase concentrations of BCRP substrate drugs (eg, rosuvastatin) and P-Glycoprotein (P-gp) substrate drugs (eg, digoxin), which may require a dose reduction of the BCRP and P-gp substrate drug.

Adverse Reactions

  • Serious adverse drug reactions in the ITP double-blind studies were febrile neutropenia, diarrhea, pneumonia, and hypertensive crisis, which occurred in 1% of TAVALISSE patients. In addition, severe adverse reactions occurred including dyspnea and hypertension (both 2%), neutropenia, arthralgia, chest pain, diarrhea, dizziness, nephrolithiasis, pain in extremity, toothache, syncope, and hypoxia (all 1%).
  • Common adverse reactions (≥5% and more common than placebo) from FIT-1 and FIT-2 included: diarrhea, hypertension, nausea, dizziness, ALT and AST increased, respiratory infection, rash, abdominal pain, fatigue, chest pain, and neutropenia.

Please see www.TAVALISSE.com for full Prescribing Information.

To report side effects of prescription drugs to the FDA, visit www.fda.gov/medwatch or call 1-800-FDA-1088 (800-332-1088).

TAVALISSE and TAVLESSE are registered trademarks of Rigel Pharmaceuticals, Inc.


About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company’s first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product has been approved by the European Commission for the treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments and will be marketed in Europe under the name TAVLESSE® (fostamatinib).

Fostamatinib1 is currently being studied in a Phase 3 trial for the treatment of warm autoimmune hemolytic anemia (AIHA); an NIH/NHLBI-Sponsored Phase 2 trial for the treatment of hospitalized COVID-19 patients, in collaboration with Inova Health System; and a Phase 2 trial for the treatment of COVID-19 being conducted by Imperial College London. Additionally, Rigel plans to launch a Phase 3 clinical trial of fostamatinib for the treatment of hospitalized COVID-19 patients in the fourth quarter of 2020.

Rigel’s other clinical programs include an ongoing Phase 1 study of R8351, a proprietary molecule from its interleukin receptor associated kinase (IRAK) inhibitor program, and an ongoing Phase 1 study of R5521, a proprietary molecule from its receptor-interacting protein kinase (RIP) inhibitor program. In addition, Rigel has product candidates in clinical development with partners AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.

1 The product for this use or indication is investigational and has not been proven safe or effective by any regulatory authority.


Forward Looking Statements
 
This release contains forward-looking statements relating to, among other things, the safety, tolerability, design, timing and results of Rigel’s products, product candidates and clinical trials. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “potential,” “may,” “expects” and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based on Rigel’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the commercialization and marketing of TAVALISSE; risks that the FDA, EMA or other regulatory authorities may make adverse decisions regarding fostamatinib; risks that TAVALISSE clinical trials may not be predictive of real-world results or of results in subsequent clinical trials; risks that TAVALISSE may have unintended side effects, adverse reactions or incidents of misuses; the availability of resources to develop Rigel’s product candidates; market competition; as well as other risks detailed from time to time in Rigel’s reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. In addition, the COVID-19 pandemic may result in further delays in Rigel’s studies, trials and sales, or impact Rigel’s ability to obtain supply of TAVALISSE. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

IR Contact: David Burke 
Phone: 650.624.1232
Email: [email protected]

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rigel-announces-two-posters-highlighting-tavalisse-at-the-62nd-ash-annual-meeting–exposition-301186305.html

SOURCE Rigel Pharmaceuticals, Inc.